erGenetics
(540) 878-8276
Email: erGenetics@erGenetics.com

  • Contact
  • Home
  • About
  • Services
    • Director Coverage & Case Sign Out
    • Consulting
    • Education & Training
  • Resources
  • Testimonials

Resources

Meloni-Ehrig A. The Cytogenetics of Hematologic Neoplasms. In: The Principle of Clinical Cytogenetics. 3rd Edition. Gersen SL, Keagle MB, Editors. Springer, New York. 2013: 309-70.

Cytogeneticist Dr. Aurelia Meloni-Ehrig has authored or coauthored over 100 peer-reviewed articles and book chapters, with special interests in cancer cytogenetics and FISH. Below you will find links to a sampling of her works as well as other relevant articles in the field.

Meloni-Ehrig A. The Cytogenetics of Hematologic Neoplasms. In: The Principle of Clinical Cytogenetics. 3rd Edition. Gersen SL, Keagle MB, Editors. Springer, New York. 2013: 309-70.

Meloni-Ehrig A. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Atlas Genet Cytogenet Oncol Haematol. 2017.

Meloni-Ehrig AM. T(7;11)(p15;p15) NUP214/HOXA13. Atlas Genet Cytogenet Oncol Haematol. 2017.

Meloni-Ehrig A. Hertzberg L. Plasmablastic lymphoma (PBL). Atlas Genet Cytogenet Oncol Haematol. 2016.

Meloni-Ehrig AM. t(X;14)(q28;q11.2) TRA-TRD/MTCP1; t(X;7)(q28;q34) TRB/MTCP1. Atlas Genet Cytogenet Oncol Haematol. 2016.

Dai Z, Kelly JC, Meloni-Ehrig A, et al. Incidence and Patterns of ALK FISH Abnormalities Seen in a Large Unselected Series of Lung Carcinomas. Mol Cytogenet 2012;5:44.

Meloni AM, Dobbs RM, Pontes JE, Sandberg AA. Translocation (X;1) in Papillary Renal Cell Carcinoma A New Cytogenetic Subtype. Cancer Genet Cytogenet. 1993;65:1-6

Kelly JC, Shahbazi  N, Scheerle J, et al. Insertion (12;9)(p13;q34q34): a cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia. Cancer Genet Cytogenet. 2009;192:36-39.

Taddesse-Heath L , Meloni-Ehrig A , Scheerle J, et al. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Modern Pathol. 2010;23:991–999.

Meloni AM, Peier AM, Haddad FS, et al. A new approach in the diagnosis and follow-up of bladder cancer, FISH analysis of urine, bladder washings, and tumors. Cancer Genet Cytogenet. 1993;71:105-18.

Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375-2390.

Arber DA, Orazi A, Hasserjian A, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405

August 21, 2012. Why FISH for ALK Testing (and PCR for EGFR and KRAS) in NSCLC? Webinar Presentation. AmeriPath, Orlando, FL. (see graphic below)

Incidence and Patterns of ALK FISH Abnormalities

Dr. Meloni-Ehrig was awarded Grant #CA41183 by the National Cancer Institute in 1990; as a research scientist, Dr. Meloni-Ehrig studied molecular aspects in solid tumors (see graphic below).

Dr. Meloni-Ehrig was awarded Grant #CA41183 by the National Cancer Institute in 1990

To inquire about our services, please call erGenetics at 540 878-8276 or contact us online. We look forward to speaking with you and appreciate the opportunity to partner with your organization.

Please note: It may take a few minutes to download articles if you are using a slow internet connection. If you are unable to view these articles, you may need to download Adobe Acrobat for free by clicking on the icon below.

Adobe Reader

erGenetics Blog

Be sure to check out our blog to stay on top of the latest research and advancements in cytogenetics. We’ll share news and resources as well as client success stories pertaining to cancer cytogenetics. You won’t want to miss it!

Learn more

Footer

  • Home
  • About
  • Services
  • Resources
  • Testimonials
  • Contact Us
  • Hippa Privacy Policy
  • Sitemap

Copyright © erGenetics. All rights reserved

iHealthspot Medical Website Design and Medical Marketing by iHealthSpot.com

Founded by Dr. Aurelia Meloni-Ehrig and Dr. Zunyan Dai, erGenetics provides professional clinical laboratory genetic director coverage, case sign out, consulting services, and training and education, particularly in the field of cancer cytogenetics and molecular genetics.